Can Eli Lilly's New Drugs Fuel Growth Beyond Its GLP-1 Blockbusters?
June 30, 2026 · 8 sources · High impact · Updated Jul 21, 2026
Eli Lilly is exploring new drug development to diversify its growth beyond its successful GLP-1 blockbusters. Meanwhile, Johnson & Johnson is facing challenges with patent losses and MedTech, despite a strong Q2 performance and an increased 2026 outlook.
Affected Companies
Affected Industries
AlphaOS aggregates and analyzes market news to extract structured investment intelligence. Content is for research and education only — not investment advice.